Technology
Health
Pharmaceutical

Ocular Therapeutix

$2.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (7.32%) Today
-$0.06 (-2.27%) After Hours

Why Robinhood?

You can buy or sell OCUL and other stocks, options, ETFs, and crypto commission-free!

About

Ocular Therapeutix, Inc. Common Stock, also called Ocular Therapeutix, is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Read More Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Employees
167
Headquarters
Bedford, Massachusetts
Founded
2006
Market Cap
113.09M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
500.11K
High Today
$2.75
Low Today
$2.47
Open Price
$2.47
Volume
462.15K
52 Week High
$8.28
52 Week Low
$2.35

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America

News

Yahoo FinanceMay 21

Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight

All eyes are on the tech sector after President Trump escalated the trade war with China by putting Chinese crown jewel Huawei on a blacklist.

183
Seeking AlphaMay 10

Ocular Therapeutix, Inc. CEO Antony Mattessich on Q1 2019 Results - Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:04 AM ET Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2019 Earnings Conference Call May 10, 2019, 08:30 AM ET Company Participants Antony Mattessich - President and CEO Donald Notman - CFO Scott Corning - SVP, Commercial Michael Goldstein - CMO Conference Call Participants Dan Leone - Raymond James Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeutix First Quarter Earnings Confe...

325
Yahoo FinanceMay 2

Ocular Therapeutixâ„¢ To Report First Quarter 2019 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutixâ„¢, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2019 financial results on Friday, May 10, 2019. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:30 a.m. Eastern Tim...

306

Earnings

-$0.54
-$0.48
-$0.43
-$0.37
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.42 per share
Actual
-$0.45 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.